Form 4 for ANIX Anixa Biosciences Inc
Accepted 2022-09-16 00:00:00 ET · period of report 2022-09-15 · accession 0001493152-22-026121 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-16 | 2022-09-15 | ANIX | KUMAR AMIT | CEO, Dir | M - OptEx | $2.58 | +640.0K | 954.0K | +204% | +$1.65M |
| D | 2022-09-16 | 2022-09-15 | ANIX | KUMAR AMIT | CEO, Dir | F - Tax | $4.48 | -491.9K | 462.1K | -52% | -$2.20M |
| D | 2022-09-16 | 2022-09-15 | ANIX | KUMAR AMIT | CEO, Dir | M - OptEx | $0.00 | -640.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-15 | M | A | 640,000 | $2.58 | 954,000 | D | — | — | |
| 2 | Common | Common Stock | 2022-09-15 | F | D | 491,900 | $4.48 | 462,100 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2022-09-15 | M | D | 640,000 | $0.00 | 0 | D | $2.58 · 2012-09-19 to 2022-09-19 | 640,000 Common Stock | (F2) Right-To-Buy, pursuant to a stock option grant dated September 19, 2012. |